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Abstract 
Cardiac resynchronisation therapy is recommended in international guidelines for 
patients with heart failure due to important left ventricular systolic dysfunction (or 
HEFREF) and ventricular conduction tissue disease. Cardiac magnetic resonance 
(CMR) represents the most powerful imaging tool for dynamic assessment of the 
volumes and function of cardiac chambers but is rarely utilised in patients with CRT 
due to limitations on the device, programming and scanning. In this review we 
explore the known utility of CMR in this cohort with discussion of the risks and 
potential benefits of scanning whilst CRT is active, including a practical strategy for 
conducting high quality scans safely. Our contention is that imaging in patients with 
CRT could be improved further by keeping resynchronisation therapy active with 
resultant benefits on research and also patient outcomes. 
 
Key words: Heart failure, cardiac resynchronisation therapy, cardiac magnetic 
resonance,  
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Introduction 
In addition to survival benefits, cardiac resynchronisation therapy (CRT) can improve 
symptoms and functional capacity in patients with left ventricular systolic dysfunction 
and conduction delay [1-3]. Consequently CRT has a class 1a level of 
recommendation in both European and American guidelines for symptomatic 
patients with prolonged QRS duration on ECG and severe left ventricular systolic 
impairment [4, 5]. 
 
Cardiovascular magnetic resonance (CMR) is accepted as the gold standard 
imaging modality for assessing cardiac volumes, mass and ejection fraction [4]. CMR 
also has an important role in the assessment of myocardial fibrosis, ischaemia and 
viability. The pattern of scarring can be helpful in differentiating the aetiology of heart 
failure including ischaemic or dilated cardiomyopathy. CMR can also contribute to 
the diagnoses of rarer conditions such as myocarditis, sarcoidosis and 
haemochromotosis. In most of these diseases, the extent of scarring also provides 
powerful prognostic information [6]. There are no data to describe the rate of use of 
CMR in CRT patients either for follow-up or for the diagnosis of other cardiovascular 
and non-cardiovascular problems, but we expect this is very low.  
 
The advent of magnetic resonance (MR) conditional pacemakers and devices could 
offer the exciting opportunity to assess specifically the effect of biventricular pacing 
on cardiac volumes and function using the most reproducible imaging technique. 
Indeed the recent joint statement from the British Cardiovascular Society and the 
Clinical Imaging Board indicates the safety of using CMR in device patients [7]. 
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However, the majority of devices disable left ventricular pacing when put into the 
CMR-scan mode. Thus, the images obtained are limited by dyssynchrony associated 
with the intrinsic underlying conduction delay or right ventricular pacing. Whilst some 
aspects of left ventricular remodelling can be assessed, the entire dataset must be 
interpreted with the proviso that the patient is being imaged while in a non-routine 
rhythm that may negatively impact contractile function and valvular regurgitation [8]. 
Ideally, any assessment of cardiac function should take place with CRT enabled. In 
this review we consider the role of CMR prior to implantation and how it could be 
utilised following CRT implantation. 
 
CMR prior to CRT Implantation 
Indication 
Late gadolinium enhancement (LGE) imaging, unique to CMR is able to identify scar, 
adding further diagnostic and prognostic information [9] and since the severity of 
scarring predicts the remodelling response[10], may also have a role in identifying 
those most likely to respond. Specifically, a large volume of scar (>33%) and 
transmurality (>51%) are predictors of a poor response to CRT [11]. A larger scar 
mass and percentage is also associated with a greater incidence of appropriate 
implantable cardioverter defibrillator (ICD) therapy [12] which might be relevant in 
future pre-implant discussions regarding the need for CRT with a defibrillator (CRT-
D) or without (CRT-P). Furthermore, mid-wall fibrosis in non-ischaemic 
cardiomyopathy patients receiving CRT, predicts a poorer prognosis, closer to that of 
those with an ischaemic aetiology [13]. 
 
Response and left ventricular lead placement  
Koshy et al. Time to scan with CRT on? Europace EUPC-D-18-01019 R1 5 
 
Whilst CMR can be used for visualisation of the coronary vein for LV lead 
implantation it is arguably more valuable in identifying areas that should be avoided 
[14, 15]. Combining scar data with non-contact endocardial mapping to identify areas 
of slow conduction allows for an optimisation of haemodynamic response,[16] whilst 
combining scar data with regional contractility data can also predict long-term 
remodelling response more effectively than standard echocardiography [17]. A large 
study (n=559) conducted by Levya et al [18] combining coronary angiography with 
CMR imaging (figure 1) described that avoiding scar improved response to CRT, 
resulting in fewer hospitalisations and death.  
 
Hence, it seems that CMR is a valuable tool to optimise CRT lead position. 
Importantly, these studies were predominantly carried out before the advent of MR 
conditional CRT devices such that none used CMR to assess outcomes. 
 
Imaging following CRT implant 
Current methods of imaging with CRT active for optimisation and response 
CRT leads to a more coordinated contraction of both ventricles, and implantation is 
associated with acute haemodynamic improvements [19] as manifested by reduced 
mean pulmonary capillary wedge pressure, systolic pulmonary artery pressure and 
left ventricular end-diastolic pressure one month after implantation [2], and 
improvements in left ventricular structure and function [23]. 
 
There are limited data confirming the clinical benefits of post-implant CRT 
optimisation of atrio-ventricular and ventricular-ventricular timing. Contractility via 
invasive dP/dtmax is accurate and reproducible but inconvenient and invasive, making 
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it often only practical at the time of implantation [20, 21]. Therefore, non-invasive 
echocardiographic optimisation has become routine. However, the variability in 
chamber volume estimation is too great to be clinically useful and timing optimisation 
therefore focuses on the timings of valvular flows, contraction measured by tissue 
Doppler imaging, or strain imaging each of which are of limited clinical value, are 
time consuming and relate poorly to haemodynamic variables [22-24].  
 
Ventricular reverse modelling is a key marker of response to CRT. There is a reliable 
and close association between improved ventricular structure and function, usually 
assessed by echocardiography following drug or device intervention and the benefits 
of that treatment on mortality [25, 26].  
 
Current and potential roles of CMR following CRT implantation 
It is possible to scan patients with CRT devices whilst the MR safe mode is 
activated, however the compliant mode is typically RV pacing rather than 
biventricular pacing. There are two issues with this: firstly, scans will not be 
representative of normal CRT function in the patient.  Moreover, RV pacing is 
associated with worse haemodynamics, worse mitral regurgitation, autonomic 
dysfunction, regional blood flow abnormalities and the dyssynchrony can lead to 
difficulties with volume and dimension analysis [1, 27]. 
 
Hence, in order to achieve a comprehensive and reliable assessment of heart 
function in the SDWLHQW¶V XVXDO VWDWH WKH ORQJ-term goal must be to image with 
biventricular pacing activated. This has a series of potential benefits that are not 
currently possible: 
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1) Optimisation ± Left ventricular volumes and cardiac output (using cine and/or 
phase contrast imaging) could be quantified for various CRT settings to 
identify optimal settings for individual patients. 
2) Assessment of non-response ± Bertini et al [28] have shown that CMR is a 
valuable tool for identifying appropriate lead placement. Approximately one 
third of patients do not respond to CRT in terms of symptoms or reverse 
remodelling [29]. With biventricular pacing active it would be possible to 
assess true ventricular wall movement of people who have responded poorly 
or not at all to CRT. 
3) Monitoring ± Ventricular function is likely to change following CRT 
implantation. This will largely be through a combination of remodelling and 
reverse remodelling. By directly visualising cardiac volume and movement it 
would be easier to identify any significant change in functionality and enables 
the possibility of further optimisation. 
4) An extremely valuable tool for research ± Due to its high versatility and low 
inter-study variability, CMR is a powerful platform. A single scan gives 
significant data and can be virtually re-run to obtain desired outputs giving 
increased value [30]. A number of key areas could be investigated further: 
a. As the gold standard in assessing the RV, it would be useful to monitor 
changes in function with CRT active. RV remodelling may differ to the 
LV and also correlate with other parameters such as quality of life. 
b. Upgrading from RV to CRT pacing suggests improved perfusion and 
function using single photon emission computed tomography [31]. 
CMR could more accurately assess the improvements without 
exposure to radiation. With the use of late gadolinium areas of 
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ischaemia could be easily identified and potentially acted on via 
percutaneous intervention. 
c. Analysing blood flow ± Aortic and pulmonary flow can be accurately 
visualised using phase contrast or 4d flow techniques  to quantify 
haemodynamic response to CRT [32]. 
d. Quantifying and predicting beneficial and adverse left ventricular 
remodelling ± CMR is superior to most other techniques in measuring 
LV volumes [33], thus it could be utilised to predict and accurately track 
this disease process [34].  
 
Therefore, as the most reliable and reproducible method of determining changes in 
LV structure and function, CMR has a high potential to become an integral part of the 
follow-up program for patients with CRT assessing both response and the effects of 
optimisation.  The limiting factors are accessibility, patient acceptability and being 
more cumbersome than other technologies such as echocardiography. In general, a 
CMR scan takes longer to complete than an echocardiogram at around 45 minutes. 
This depends largely on the scanning sequence used, the base heart rate of the 
patient (a faster heart rate giving slightly faster scans), the specific question being 
asked and patient compliance. Thus, in the future CMR might initially develop into a 
test undertaken in patients with a suboptimal response to CRT. 
 
Important procedural aspects of CMR after CRT implantation 
Safety: Potential risks of CMR to a pacemaker patient 
Prior to the advent of MR conditional devices there were concerns that pacemaker 
devices being exposed to high strength magnetic fields and radiofrequency pulses 
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could lead to transient or permanent damage to the battery, circuitry, leads or the 
heart itself [35, 36]. It became apparent that the multiple electromagnetic fields can 
create vibration and heating within the generator and leads through the induction of 
current. This in turn can give inappropriate sensing of the leads causing a failure to 
pace or a device malfunction including a reset. Reluctance from physicians to 
commit patients to a MR scan formed, potentially impacting on patient care [37]. 
 
The concerns led to industry redeveloping devices and programming options to 
improve MR tolerance. Devices have minimised their ferromagnetic content and 
gained solid state technology. Furthermore, filters are used reducing transmission of 
certain frequencies within the device and leads thus limiting detrimental energy 
WUDQVIHUZLWKVRIWZDUHFRPSOHPHQWLQJ³05VDIHPRGH´[38]. The proprietary MR safe 
mode can only be initiated after a rigorous device integrity check. Once initiated it 
locks out settings that would otherwise cause interference and susceptibility with 
magnetic field exposure. Despite the ability to scan patients with a number of 
therapies are active, there are no known studies investigating this area using CMR. 
 
There are also issues with the rate of energy transfer to healthy tissue via MR. The 
specific absorption rate is often unremarkable in the majority of cardiac scans; 
however it can accumulate with certain pulse sequences such as 4D flow and 
stronger magnetic field strengths such as 3.0T or above. Importantly, safety limits 
are built into scanning software with warnings and automatic cut-off when beyond 
reasonable thresholds. Fortunately issues around high specific absorption rate 
exposure are transient with few recorded significant events and no known associated 
long term effects [39]. 
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Following a series of studies finding minimal interaction with MR and cardiac 
devices, the European Society of Cardiology deemed in 2008 that patients with 
implanted devices could undergo a magnetic resonance imaging scan if appropriate 
safety considerations were made [40]. Large scale studies have shown that neither 
non-cardiac nor cardiac scans are associated with death, device or lead failure in 
this context (table 1). Furthermore, complications are temporary and only in the 
rarest of incidents have resulted in subsequent intervention required; such cases are 
often related to violations of modern scanning safety protocol. 
 
Pre-scan device checks 
Most modern implanted CRT devices are labelled as MR conditional resulting in a 
relatively standard protocol across hospitals. Prior to each MR scan, cardiac or 
otherwise, a routine device check is conducted. This is primarily to establish a 
baseline set of parameters including lead sensing, voltage threshold and lead 
impendence. Each major manufacturer has a MR safe mode that vary slightly (table 
2), derived from pre-clinical and clinical testing, though typically involve either AOO 
or DOO pacing with high outputs. Most manufacturers (except Biotronik and Boston 
Scientific) disable CRT; furthermore if bradycardia pacing is required it is achieved 
with high output RV VOO pacing. It is advised that a device check is conducted 
before changing device settings to an MR compatible mode.  
 
Monitoring 
When altering pacemaker settings it is crucial to confirm the resultant rhythm is not 
detrimental to the patient; a cardiac monitor should be in place throughout the scan 
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with regular patient contact. Notably, some changes such as varying voltage can be 
uncomfortable to the patient by causing phenomenon such as muscle twitching and 
diaphragmatic stimulation via high output RV pacing. Once the scan is complete, the 
device is reverted to pre-scan settings and followed up with a repeated device check 
focusing on the leads and battery. This ensures that neither the patient or device 
have been negatively affected during the scan nor are at future risk. 
 
Image quality optimisation 
In the presence of an implanted cardiac device, cardiac scanning is particularly 
associated with artefacts that can make the images more difficult to interpret [41] 
(figure 2). 
 
Most relevant for implanted devices are susceptibility artefacts. These are created by 
the difference in magnetic properties of distinct tissue and materials. This interaction 
causes protons to become dephased giving bizarre patterns on the image [42]. 
Metallic objects or those interfacing with air often cause distortions manifesting as 
areas of increased or absent signal. Pacemakers cause susceptibility artefacts 
primarily from the generator rather than the leads (due to increased metal content), 
an issue exacerbated at higher magnetic field strengths. 
 
In order to counter these, particular scanning protocols are employed. Currently, the 
most common technique for cine imaging in patients without a cardiac device is 
steady-state free precession (SSFP.) Prior to the development of SSFP, gradient 
echo (GRE) was widely used. It was superseded due to reduced tissue contrast and 
requiring longer breath-hold. In device patients, GRE has been shown to produce 
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fewer artefacts and non-diagnostic images than balanced SSFP with image quality 
significantly better for both the left and right ventricle [43]. Thus, in patients with 
cardiac devices and suboptimal balanced SSFP imaging, GRE is a useful option. 
Scanning techniques are developing at a rapid rate; notably the recent study by 
Hilbert et al [44] has confirmed the utility of alternative protocols to help produce 
diagnostic grade images. 
 
LGE imaging can be used with both SSFP and GRE for tissue characterisation to 
delineate areas of scar. Conventional LGE imaging is vulnerable to hyperintensity 
artefacts particularly from the generator which appears bright on the image. This 
artefact can either be inappropriately misdiagnosed as scar or impair imaging to the 
extent that it is non-diagnostic. This problem can be overcome by the use of 
wideband LGE in which the myocardial nulling caused by the device artefact can be 
overcome by using a wider band inversion pulse [45]. Since patterns of interference 
are not consistent it is likely that tailored scan settings for manufacturers and device 
types will be developed to reduce artefacts [46]. Importantly, whilst LGE does not 
require any further equipment or processing time, it is associated with increased 
specific absorption rate by approximately 20% when compared with routine scans 
[47]. 
 
The need for GRE increases the duration of the scan and may prolong breath 
holding which is a particular problem for patients with CHF. Future technical 
advances to reduce acquisition time and breath-holding will be particularly beneficial 
in this patient group. Renal impairment is also a concern and often co-existent with 
heart failure, potentially prohibiting the use of gadolinium based contrast agents. 
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Potential process of CMR scanning with CRT on 
There are challenges in scanning a patient with CRT active which can largely be 
overcome with recent advances in both device and CMR technology. We propose a 
protocol for patients with implanted CRT devices to streamline scanning (figure 3) 
which limits artefacts, maintains de facto CMR image standards and ensures patient 
safety and comfort. 
 
Patient safety is paramount and maintained by deviating minimally from current CMR 
procedure and a high level of due diligence with regards to device review. Artefact 
limitation can be achieved with relatively simple measures. Appropriate positioning of 
the patient in the scanner and careful skin preparation to avoid incorrect ECG 
triggering help obtain high quality images. A GRE scan can be used to obtain images 
quickly and mitigate artefacts from devices in situ. Experienced radiographers and 
cardiac physiologists must be involved to reduce artefacts and maximise safety. 
Ideally, a CMR imaging expert should also be present to facilitate live adjustment of 
the imaging process to ensure that the images obtained are of the highest quality 
and subsequently enable a robust analysis. If CRT optimisation is required, the scan 
can be repeated altering variables such as A-V and V-V delay. With improvements in 
wireless communication particularly Bluetooth technology, it is feasible that CRT 
programming could be changed whilst the patient remains in the scanner. This 
approach would allow left ventricular volumes and cardiac output (using cine and/or 
phase contrast imaging) to be easily quantified for each CRT setting, identifying 
optimal settings for each patient. 
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It is important that in a time of rapidly improving technologies, persistent efforts are 
made to maximise on the potential outcomes for patients. We look forward to pilot 
and randomised studies investigating the utility of CMR in this cohort. Scanning 
patients with CRT active is likely not only viable but an important step in optimising 
therapy and the responder rate. Indeed the sheer utility of CMR may represent a 
model shift in care for patients post implantation. 
 
Conclusions 
CMR offers significant utility in patients with heart failure; furthermore, advances in 
CMR and CRT technology mean that scanning with CRT active is feasible. To 
achieve this routinely in both a clinical and research setting, a multidisciplinary 
working approach is required with cardiac physiologists, MR radiographers, imaging 
experts and clinicians. This could lead to significant benefits including device 
optimisation, improved patient selection, prognostication and understanding 
mechanisms of non-response.  
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Figures 
 
Figure 1 ± Adapted from Levya et al [18] with permissions kindly received from 
BioMed Central. Mapping LV lead positions. The longitudinal distance from the 
atrioventricular plane to the lead tip, in a base-to-apex direction, is quantified using 
the 30° right anterior oblique fluoroscopic view (A). This longitudinal distance is 
transposed to the four-chamber CMR view (B), so as to determine the LGE-CMR 
short axis slice (yellow line, C) that corresponds to the LV lead tip position. The 30° 
left anterior oblique fluoroscopic view (D) is then used to determine the 
circumferential position (yellow arrow). The longitudinal and circumferential 
coordinates permit localization of the LV lead tip in relation to myocardial segments 
and myocardial scars, which appear as white enhancement on LGE-CMR (white 
arrow).  
 
Figure 2 ± Imaging strategies to decrease the artefact in patients. Steady state free 
precession imaging is commonly used but is associated with artefacts in patients 
with CRT-D (A). The artefact can be reduced by using a gradient echo sequence, 
albeit at the cost of a longer breath-hold and less contrast between myocardium and 
blood pool (B). Conventional late gadolinium enhancement imaging is impaired by 
severe artefact making identification of the apical myocardial infarction difficult (C). 
The imaging is improved by use of a wideband late gadolinium enhancement 
sequence, where the apical myocardial infarction can be clearly seen, marked as a 
red asterix (D).  
 
Figure 3± Flow chart of the potential approach to scanning patients with CRT 
devices and biventricular pacing active including CMR. (A) Still images of the 
planning survey with artefact (white asterisk) from the device generator, (B) cine 
scan with LV and RV lead artefacts (blue and red asterisks respectively), (C) 
ischaemia testing with perfusion defect indicating septal wall infarct (red arrow) and 
(D) scar assessment also identifying lateral wall infarct (blue arrow).  
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Tables 
Table 1 ± Large trials (n>100) of MRI scanning in patients with implanted cardiac 
devices 
Author Year of 
publication 
Number of 
patients 
scanned 
Device 
type 
MRI 
conditional 
MRI 
Field 
strength 
(Tesla) 
MRI 
scanning 
protocol 
Significant 
complications 
Hilbert et 
al [44] 
2018 128 CRT, 
ICD & 
PM 
Mixture 1.5 Cardiac None (No 
changes to 
device 
performance or 
adverse events 
were observed) 
Lupo et 
al [48] 
2018 120 ICD & 
PM 
No 1.5 Routine 
including 
cardiac 
No adverse 
events were 
observed. One 
temporary 
communication 
failure was 
observed 
(0.08%). 
Nazarian 
et al [49] 
2017 1509 ICD & 
PM 
No 1.5 Routine 
including 
cardiac 
In 9 
examinations 
(0.4%) the device 
reverted to a 
transient back-up 
programming 
mode without 
long-term effects. 
Ching et 
al [50] 
2017 140 PM Yes 1.5 Cardiac None 
Mason et 
al [51] 
2017 178 ICD & 
PM 
Mixture 
(82% non-
conditional) 
1.5 Routine 
including 
cardiac 
None 
Russo et 
al [52] 
2017 1246 ICD & 
PM 
No 1.5 Routine 
excluding 
thoracic 
One patient 
required 
generator 
replacement 
following 
scanning whilst 
in unsafe device 
settings. In 6 
examinations 
(0.04%) the 
device reverted 
to a transient 
back-up 
programming 
mode without 
long-term effects. 
Schwitter 
et al [53] 
2016 156 ICD Yes 1.5 Cardiac None 
Higgins 
et al [54] 
2016 398 ICD & 
PM 
No 1.5 Routine 
including 
cardiac 
None 
Bailey et 
al [55] 
2016 221 PM Yes 1.5 Cardiac & 
Thoracic 
spine 
One adverse 
event (0.4%) 
possibly related 
to the implanted 
system and scan. 
Awad et 
al [56] 
2015 153 ICD Yes 1.5 Cardiac & 
Thoracic 
None 
Koshy et al. Time to scan with CRT on? Europace EUPC-D-18-01019 R1 18 
 
spine 
Shenthar 
et al [57] 
2015 177 PM Yes 1.5 Routine 
including 
cardiac 
None 
Friedma
n et al 
[58] 
2013 171 PM Mixture 1.5 Routine 
including 
cardiac 
None 
Schwitter 
et al [59] 
2013 150 PM Yes 1.5 Cardiac None 
Gimbel 
et al [60] 
2013 177 PM Yes 1.5 Chest 
and head 
None 
Nazarian 
et al [61] 
2011 438 ICD & 
PM 
No 1.5 Routine 
including 
cardiac 
In 3 patients 
(0.007%) the 
device reverted 
to a transient 
back-up 
programming 
mode without 
long-term effects 
Wilkoff et 
al [62] 
2011 258 PM Yes 1.5 Head and 
lumbar 
spine 
None 
Strach et 
al [63] 
2010 114 PM No 0.2 Routine 
excluding 
cardiac 
None 
Mollerus 
et al [64] 
2010 103 ICD & 
PM 
No 1.5 Routine 
including 
cardiac 
One pacemaker 
reverted to 
transient back-up 
programming 
requiring 
reprogramming 
CRT ± Cardiac resynchronisation therapy, ICD - Implantable cardioverter 
defibrillator, MRI ± Magnetic resonance imaging, PM ± Pacemaker (conventional and 
dual chamber pacemakers). 
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 Table 2± Comparing default MR compatible settings between major CRT 
manufacturers.  
BiV ± Biventricular, RV ± Right ventricle,  
Parameter Abott (Previously 
St. Jude Medical) 
settings 
Biotronik 
settings 
Boston 
Scientific 
settings 
Medtronic 
settings 
Lead paced RV BiV or RV BiV or RV RV 
Tachycardia 
therapy 
disabled? 
Yes Yes Yes Yes 
CRT disabled? Yes Yes No Yes 
HR range 30-120 70-160 30-110 30-120 
Increase output? Yes, increased to 5V 
with 1ms as support 
lead (de facto) 
Yes Yes Yes 
Fixed pacing 
mode (non-
sensing) 
Yes (Reverts to VOO, 
AOO, DOO) 
Yes Yes Yes 
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Supplementary material 
Comparing SSFP and GRE 4 chamber MRI views.mp4
 
Video 1 ± Cine CMR in a 49 year old female with CRT active at 90bpm (DOO) over 1 
second, showing improved image acquisition can be improved from steady state 
free-precession (SSFP) on the left with a gradient echo (GRE) sequence on the 
right. This produces significantly less artefact.  
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